In 2018, Ian C. Read earned $5.67M in total compensation at Pfizer, including $2.00M salary and $3.00M bonus. Most recently sold 530,078 shares in Mar 2019. Currently holds stock worth $41.92M. Has donated $191.72K in stock to charitable causes. Led Pfizer as CEO for 8 years.
Compensation History
Annual executive compensation data for Ian C. Read, including salary, bonuses, and stock awards.
Year
2018
Total Compensation
$5.67M
Salary
$2.00M
Bonus
$3.00M
Other
$671.85K
Salary
$2.00MBoard Justification
Pfizer's compensation philosophy is designed to align executive pay with performance, ensuring that a significant portion of total compensation is at risk and tied to the company's financial and operational success.
Bonus
$3.00MBoard Justification
The annual incentive award for 2018 was based on performance metrics including revenue, adjusted diluted EPS, and cash flow from operations, with a total payout of $3,000,000.
Other Compensation
$671.85KBoard Justification
Other compensation includes perquisites such as financial counseling, home security, and personal use of company aircraft.
Restricted Stock
Board Justification
No stock awards vested in 2018 as the focus is on the performance share awards and stock options that are not included in the total compensation calculation.
Performance Metrics
The performance metrics for determining Ian Read's compensation included total revenue, adjusted diluted EPS, and cash flow from operations.
Ian C. Read
Ex-CEO of Pfizer
Education
Bachelor's degree in Economics from the University of Strathclyde and an MBA from the Wharton School of the University of Pennsylvania
Field of Expertise
Healthcare & Life Sciences - Pharmaceuticals
Sector of Economy
Healthcare
Born
March 21, 1954 - 71 years ago
CEO of Pfizer for
8 years 0 months (Dec 2010 - Dec 2018)
Previous Experience
Joined Pfizer in 1978, held various positions including President of Worldwide Pharmaceutical Operations.
Holdings
Track Ian C. Read's stock holdings and portfolio value over time.
Total Stock Sold
$83.94M
$83.94M
2,311,949 PFE shares
What if they kept their stock?
If Ian C. Read didn't sell their stock, today they would have:
Extra PFE2,311,949 shares worth $59.42M.
This is -29.22% and $24.53M less than what they got when they sold the stock.
Charitable Transactions
7,460 shares
PFE
Recent Charitable Transactions
7,460 shares
PFE
Dec 14, 2017
Charity
Insider Trading
Ian C. Read's recent stock transactions, purchases, and sales filed with the SEC.
$22.96M
PFE at $43.31/share
Mar 4, 2019
Sale
$2.20M
PFE at $43.26/share
Mar 4, 2019
Sale
347,327 shares
PFE
Feb 27, 2019
Received
$18.21M
PFE at $37.42/share
Jul 16, 2018
Sale
$4.77M
PFE at $36.03/share
May 1, 2018
Sale
286,952 shares
PFE
Feb 26, 2018
Received
7,460 shares
PFE
Dec 14, 2017
Charity
$6.70M
PFE at $34.00/share
Aug 31, 2017
Sale
$3.30M
PFE at $34.00/share
Aug 4, 2017
Sale
110,011 shares
PFE
Feb 27, 2017
Received
Rivals
Compare Ian C. Read with competitor CEOs and industry peers.
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Stanley C. Erck
CEO of Novavax
2023 Compensation
Stock
$129.78K
Salary
$50.90K
Bonus
$0.00
Other
$3.83M
Total Holdings
$4.60M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M